Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations

Modern Pathology

Volumn 19, Issue 9, 2006, Pages 1157-1163

  Cao, Dengfeng ^a,d   Antonescu, Cristina ^b   Wong, Grace ^b   Winter, Jordan ^a   Maitra, Anirban ^a   Adsay, N Volkan ^c   Klimstra, David S ^b   Hruban, Ralph H ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Immunohistochemistry; KIT; Molecular analysis; Mutation; Pancreas; Solid pseudopapillary neoplasm

Indexed keywords

KIT PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CELL COUNT; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33747598682     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800647     Document Type: Article

References (42)

1. Kosmahl M, Seada LS, Janig U, et al. Solid-pseudopapillary tumor of the pancreas: its origin revisited. Virchows Arch 2000;436:473-480.
2. Klimstra DS, Wenig BM, Heffess CS. Solid-pseudopapillary tumor of the pancreas: a typically cystic carcinoma of low malignant potential. Semin Diagn Pathol 2000;17:66-80.
3. Tang LH, Aydin H, Brennan MF, et al. Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol 2005;29:512-519.
4. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. J Am Coll Surg 2005;200:965-972.
5. Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
6. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human protooncogene KIT: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351.
7. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002;38:S3-S10.
8. Vanderback GR, deCastro CM, Taylor H, et al. Cloning and structural analysis of the human KIT gene. Oncogene 1992;7:1259-1266.
9. Gibson PC, Cooper K. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol 2002;9:65-69.
10. Popescu LM, Hinescu ME, Ionescu N, et al. Interstitial cells of Cajal in pancreas. J Cell Mol Med 2005;9:169-190.
11. Miettinen S, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of KIT. Mod Pathol 2000;13:536-541.
12. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of KIT in human gastrointestinal stromal tumors. Science 1998;279:577-580.
13. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795.
14. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
15. Corless CL, Schroeder A, Griffin D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-5364.
16. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
17. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
18. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
19. Debiec-Rychter M, Dumez H, Judson I, et al. Use of KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-695.
20. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
21. Hamilton SR, Aaltonen LA. Pathology and Genetics Tumors of the Digestive System. World Health Organization Classification of Tumors: Lyon, 2000.
22. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing KIT: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005;23:585-590.
23. Holst VA, Marshall CE, Moskaluk CA, et al. KIT protein expression and analysis of KIT gene mutation in adenoid cystic carcinoma. Mod Pathol 1999;12:956-960.
24. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23:49-57.
25. Tamborini E, Bonadiman L, Negri T, et al. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 2004;10:8214-8219.
26. Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004;10:178-183.
27. Haitel A, Susani M, Wick N, et al. KIT overexpression in chromophobe renal cell carcinoma is not associated with KIT mutation of exons 9 and 11. Am J Surg Pathol 2005;29:842.
28. Lassus H, Sihto H, Leminen A, et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 2004;91:2048-2055.
29. Pache M, Glatz K, Bosch D, et al. Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003;443:741-744.
30. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-4522.
31. Burger H, den Bakker MA, Kros JM, et al. Activating mutations in KIT and PDGFRa are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005;4:1270-1274.
32. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with KIT expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;16:1811-1816.
33. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing KIT protein: a phase II clinical trial. Cancer 2005;103:2128-2131.
34. Modi S, Seideman AD, Dickler M, et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005;90:157-163.
35. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101:126-131.
36. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-1405.
37. von Mehren M. Targeted therapy with imatinib: hits and misses? J Clin Oncol 2005;23:8-10.
38. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626.
39. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465.
40. Matsunou H, Konishi F. Papillary-cystic neoplasm of the pancreas. A clinicopathologic study concerning the tumor aging and malignancy of nine cases. Cancer 1990;65:283-291.
41. Daum O, Klecka J, Ferda J, et al. Gastrointestinal stromal tumor of the pancreas: case report with documentation of KIT gene mutation. Virchows Arch 2005;446:470-472.
42. Pauser U, da Silva MT, Placke J, et al. Cellular hamartoma resembling gastrointestinal stromal tumor: a solid tumor of the pancreas expressing KIT (CD117). Mod Pathol 2005;18:1211-1216.